Novo Resources appointed Rohan Williams as General Manager of Exploration effective April 15, 2026. Williams brings extensive experience in regional-scale exploration and geological modelling to lead the company’s Pilbara-focused drilling and resource evaluation programs.

Novo Nordisk partnered with OpenAI to deploy artificial intelligence across its drug discovery, manufacturing and commercial operations, beginning with pilot programs. The integration aims to analyze complex datasets, streamline clinical trial design, enhance regulatory preparation and optimize supply chain processes, with full implementation targeted by year-end 2026.

BMO Capital reduced its price target on Novo Nordisk shares to $36 from $45, citing potential first-quarter Wegovy Pill revenue falling about 12% short of consensus. The firm projects Q1 revenue at 881 million Danish kroner versus a 1,001 million consensus, noting prescription capture rates rose to 60% from 50%.

Novo Nordisk faces heightened competition in the obesity drug market following U.S. approval of Eli Lilly’s oral weight-loss treatment, with analysts forecasting the sector could exceed $100 billion annually within a decade. Executives view AI adoption as a strategic lever to regain momentum and boost productivity without further workforce reductions.